On September 3, 2025 Coherus Oncology, Inc. (NASDAQ: CHRS) reported that the company will be webcasting its participation in the following upcoming conferences (Press release, Coherus Oncology, SEP 3, 2025, View Source [SID1234655726]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird 2025 Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 1:25 p.m. Eastern Daylight Time / 10:25 a.m. Pacific Daylight Time
H.C. Wainwright 27th Annual Global Investment Conference in New York, NY on Wednesday, September 10, 2025, at 11:00 a.m. Eastern Daylight Time / 8:00 a.m. Pacific Daylight Time
UBS Virtual Oncology Day takes place virtually on Wednesday, October 1, 2025, at 1:00 p.m. Eastern Daylight Time / 10:00 a.m. Pacific Daylight Time
The presentations will be accessible via webcast links on the Investor Events section of the Coherus website: View Source Replays of the presentations will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective bank representative.

On September 3, 2025 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, reported the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts (Press release, Cellectar Biosciences, SEP 3, 2025, View Source [SID1234655725]). The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to present our poster at the AACR (Free AACR Whitepaper) Special Conference on Pancreatic Cancer, further showcasing the potential of CLR 121225 for solid tumors," said Jarrod Longcor, chief operating officer of Cellectar. "We are encouraged that preclinical studies to date have demonstrated excellent activity, biodistribution and uptake of CLR 225 across multiple solid tumor animal models and are currently advancing IND-enabling activities."

Details of the poster presentation are as follows:

Title: "Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225, a Novel Actinium-Based Radio-Conjugate"
Poster: B032
Date/Time: Tuesday, September 30, 6-9 p.m. Presenter: Jarrod Longcor

On September 3, 2025 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada (Press release, C4 Therapeutics, SEP 3, 2025, View Source [SID1234655721]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMS Annual Meeting 2025 Oral Presentation
Title: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Presentation Date and Time: Saturday, September 20, 2025 at 11:10 am ET
Session: Future Targets and New Modalities of Therapy
Location: Metro Toronto Convention Centre – South Building, Room 701
Presenter: Binod Dhakal, M.D., M.S., associate professor of medicine, Medical College of Wisconsin, Division of Hematology

C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM, which continues to demonstrate a well-tolerated safety profile and compelling response rates. The presentation at the IMS Annual Meeting will include data from all safety and efficacy evaluable MM patients from all dose levels studied in the cemsidomide with dexamethasone cohort in the Phase 1 trial. C4T’s investor webcast will highlight the data from the oral presentation at the IMS Annual Meeting and provide additional detail on the company’s planned next steps of clinical development.

C4T Investor Webcast
C4T will host a webcast on September 20, 2025 at 3 pm ET. To join the webcast, please visit this link or the "Events & Presentations" page of the Investors section on the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived and available following the event. Additionally, following the oral presentation at the IMS Annual Meeting, C4T will share that presentation on its website under the Scientific Presentations and Publications page.

On September 2, 2025 Abkyu, Inc., a biotechnology company specializing in single-domain antibody (VHH) discovery, reported a strategic discovery partnership with Jeevan Therapeutics, a biotechnology company founded by experienced industry leaders in biologics and small molecule development (Press release, Jeevan Therapeutics, SEP 2, 2025, View Source [SID1234656393]). The collaboration, valued at up to $200 million, will leverage Abkyu’s proprietary VHH discovery platform to accelerate the development of next-generation therapeutics aimed at addressing complex disease biology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Jeevan Therapeutics will gain dedicated access to Abkyu’s discovery platform and downstream engineering expertise to develop VHH candidates against its primary drug target. In return, Abkyu will receive an upfront payment and is eligible for additional regulatory and clinical milestone payments and commercial royalties.

"We couldn’t be more excited to partner with Jeevan Therapeutics," said Travis LeGuyader, co-founder of Abkyu. "Our platform was built specifically to enable the kind of therapeutics their team is developing and is designed to significantly increase the chances of success by identifying molecules that precisely match the target product profiles (TPPs) they are pursuing. Partnering with Jeevan not only allows us to leverage our platform to help address a largely underserved patient population but also to align with a team that shares our vision for the potential of VHHs and the breadth of their therapeutic applications."

"Partnering with Abkyu represents a pivotal step forward for Jeevan as we advance our mission to deliver transformative therapies for patients with significant unmet needs," said Terrence West, CEO and Co-Founder of Jeevan Therapeutics. "Abkyu’s cutting-edge VHH discovery platform, combined with our expertise in precision biologics and drug development, positions us to accelerate the creation of next-generation therapies designed to improve long-term patient outcomes."

This partnership reflects a shared vision to accelerate the development of next-generation biologics and expand treatment options for patients with significant unmet needs. By uniting Abkyu’s powerful VHH discovery platform with Jeevan’s innovative therapeutic strategy, the collaboration seeks to deliver therapies that set new standards for efficacy and long-term patient benefit.

On September 2, 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, reported that John Yu, MD, CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference (Press release, Kairos Pharma, SEP 2, 2025, View Source [SID1234655684]). The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Date:

September 5, 2025

Time:

Available on-demand starting at 7:00 AM Eastern Time

Webcast Link:

View Source

A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A replay of the webcast will be archived and available following the event for 90 days.

View Source

Dr. Yu will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below:

View Source